Objective To determine the range and heterogeneity of outcomes reported in randomized controlled trials of interventions for children with chronic kidney disease (CKD). (1%) were reported infrequently. The 2 most frequently reported outcomes, blood pressure and relapse/remission, had 56 and 81 different outcome measures, respectively.
S
ince the recognition of children as "therapeutic orphans" in the 1960s, there has been a wave of international efforts to improve trial-based evidence to support health interventions in children. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] The past 2 decades has seen an increase in the number of trials conducted in children since the US and Europe revised legislation on labeling of medicines to mandate pediatric data. 3 Also, major pediatric trial networks have been established globally, including the US Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Trial Network and the Network of Pediatric Research at the European Medicines Agency, to improve infrastructure and capacity for pediatric trials. 13, 14 Despite this upsurge in pediatric clinical trials, the relevance and value of trials may be limited by problems in the prioritization, design, reporting, and dissemination of research, including outcomes measured and reported. [15] [16] [17] [18] [19] [20] [21] Trials are only as informative as their outcomes, 22 yet many report outcomes that may not be relevant directly to patients and clinicians and do not involve children and caregivers in the selection of outcomes. [23] [24] [25] Analyses of pediatric trials within specific health conditions have shown that the outcomes reported are extremely variable, including the definitions and measures used, [23] [24] [25] [26] [27] which limits comparability of the effectiveness of interventions across studies. 16 Initiatives to establish core outcomes, to be reported at a minimum in all trials with specific health condition, such as The Outcome Measures in Rheumatology (OMERACT), have demonstrated improvement in the relevance and reporting of outcomes in trials, 22, 23, [28] [29] [30] although core outcome sets generally are lacking in children.
Children with chronic kidney disease (CKD) have a mortality rate up to 30 times greater than the age-matched general population, and those who progress to end-stage kidney disease depend on dialysis or a kidney transplant for survival. 31, 32 Although many trials have been conducted in children with CKD, the risk and prevalence of comorbid conditions, treatment complications, developmental problems, debilitating symptoms, such as fatigue, and impaired quality of life (QOL) remain high. [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] Improvements in healthcare and outcomes through research rely on the relevance and consistency of reported outcomes. Affected children depend on their caregivers and clinicians to provide long-term, complex, and highly technical treatments that have profound implications for their development and wellbeing. We aimed to describe the scope and consistency of outcome domains and measures in trials involving children with all stages of CKD, to inform strategies for establishing core outcomes that are important to children, families, and clinicians to be reported in trials, to inform clinical decision making, and ultimately to improve the outcomes for children with CKD.
Methods
We searched the Cochrane Kidney and Transplant Specialized Register for all randomized controlled trials involving children aged up to 21 years or younger (the upper age limit to define the pediatric population is up to 21 years in the US (Figure 1 ; available at www.jpeds.com). We used search terms relating to children and pediatrics. Trials that included more than 50% of patients aged older than 21 years were excluded. Trials that included children with chronic conditions, but did not report data from the CKD population, were not eligible.
Data Extraction
We extracted the following characteristics from each trial: publication year, setting (participating countries), sample size, mean age of participants, study duration, intervention type, and all outcomes. We defined outcome measures as any measures reported separately for all trial arms. We extracted all specifications of the outcome measures, if reported, including the outcome domain (eg, blood pressure), specific measurement (eg, percentage of hypertensive patients), method of aggregation (eg, percentage change), specific metric (between commencement and end of the trial), and time point of measurement (defined as the time frame from trial commencement to when the outcome was measured). 46 
Statistical Analyses
We categorized all the outcome measures from all the included trials into outcome domains. The first author drafted the initial list of outcome domains. This was cross-checked by 4 reviewers and revised until consensus was achieved. The outcome measures were then grouped according to the final list of outcome domains, which was re-reviewed by the same 4 reviewers. All outcome domains were further categorized as surrogate (biochemical or physiological outcomes, ie, pathophysiological manifestations of health conditions, including such as blood pressure 47 ), clinical (medical outcome of a condition or treatment), and patient-reported (outcomes reported on by patients and caregivers, typically related to how the patients function or feel in relation to a health condition or therapy), based on standard nomenclature. 48, 49 Some outcome domains included measures that straddled several categoriessurrogate, clinical, and patient-reported. Thus, classification of the domains was based on the largest proportion of outcome measures. The number of trials, and dialysis-and transplantation-specific trials that reported each outcome domain was calculated.
We conducted a detailed analysis of outcome measures of the 3 outcome domains in each category that were reported most frequently across trials, as well as the 3 pediatricspecific domains (height and pubertal development, weight/ body mass index [BMI]/body composition, and school performance). The measurement, aggregation, metric, and timing as reported in the primary studies were analyzed. We retained the original term if studies did not further define or provide details on the outcome measure. Statistical analyses of frequency were conducted with R version 3.2.3 (R Foundation for Statistical Computing, Vienna, Austria; http://www .R-project.org/).
Results
Our search yielded 1266 trials, of which 205 included 2174 children with CKD ( Table I ). The trial characteristics are shown in Table I . The number of unique outcome measures per trial (excluding time points) ranged from 1 to 64, with a median of 15 (IQR 9-26). We excluded 382 outcome measures because they were not a direct health outcome measured in patients (eg, "mean cold ischemia time, and "medication dose/use/duration") or were specific to a single intervention within a trial (eg, "number of patients monitored and educated"). The remaining 5776 were classified into The number of trials that reported a minimum of one surrogate outcome domain was 180 (87.8%), and 164 (80.0%) and 49 (23.9%) reported at least one clinical and one patientreported domain, respectively. From the 30 (30%) outcomes reported by at least 10% of trials, 17 were surrogate, 12 were clinical, and one was patient-reported. Figure 3 shows the number of outcome measures and time points of measurement for 10 outcome domains (the 3 most frequently reported surrogate and clinical outcome domains, 2 most frequently reported patient-reported domains, and 2 pediatric-specific domains). The outcome measures and time points of measurement for each outcome domain listed in Figure 3 , excluding "school performance," are shown in Figure 4 , A-I (available at www.jpeds.com).
The 3 most frequently reported surrogate outcomes were "blood pressure" (56 outcome Across the 205 trials, 109 (53.2%) did not specify the primary outcome, 68 (33.2%) specified several outcomes as primary outcomes, and 28 (13.6%) specified one unique primary outcome. The outcomes specified as primary outcomes corresponded to 36 different outcome domains: 24 (66.7%) were surrogate outcomes, 10 (27.8%) were clinical outcomes, and 2 (5.6%) were patient-reported outcomes. The 6 most frequently reported primary outcomes were "relapse/remission" (43 [ 
Discussion
Biochemical surrogate outcomes comprised more than onehalf of the outcome domains reported in clinical trials involving children with CKD, with blood pressure, kidney function, weight, and urine protein being the most frequently reported. These were much more common compared with clinical and patient-centered outcomes such as mortality (14%), cardiovascular disease (4%), and QOL (1% of trials). In terms of pediatric-specific outcomes, physical development (height and pubertal development, weight/BMI/body composition) were reported in more than 25% of trials, but school performance was assessed in only one trial. Thus, the relevance of current trials to guide treatment decisions based on outcomes that are important to children with CKD and their caregivers may be disputable. Also, there is wide heterogeneity of outcome domains reported across trials and, within each outcome domain, large variability in the definitions, time points, and measures used. Such inconsistencies in outcome reporting obscure assessments about the comparative effectiveness of interventions across trials. Surrogate outcomes such as serum biomarkers frequently are used in trials because they require a smaller sample size, shorter time frame, and fewer resources to assess effectiveness. In fe ct io n Kid ne y fun ctio n Rela pse/ rem issio n Blood pressure Hyperhidros is Mali gnan cy -Skin Pu lm on ary em bo lus Va sc ul ar ac ce ss co m pl ica tio ns P hy si ca l fu nc tio n /m ob ili ty /d is ab ili ty S ch o o l p e rf o rm a n ce V it a m in e D o n o r-s p e c if ic a n ti -H L A a n ti These may be key considerations, given the relatively small population of children with CKD, and the additional ethical and logistical requirements to conduct trials in children. Surrogate outcomes, however, have not been validated robustly in this setting and do not bear direct relevance to patients and their families. Serum phosphate, serum calcium, parathyroid hormone, and anemia/hemoglobin/iron were reported in >15% of trials, but there is no evidence to indicate that they predict mortality and cardiovascular events in patients with CKD. [49] [50] [51] [52] [53] [54] [55] Although some physiological markers may be appropriate measures of short-term disease activity for acute conditions, 56 they are arguably less informative in chronic conditions. Further studies are needed to validate surrogate outcomes such as parathyroid hormone, serum phosphate, and serum calcium.
Many outcomes that have been identified as important and clinically relevant to children with CKD were absent in most trials. Studies that have directly elicited perspectives from children living with CKD have identified their priorities as school attendance and performance, anxiety, social participation, ability to participate in physical activity, hospitalization, and fatigue. 42, [56] [57] [58] [59] [60] [61] Patient-reported outcomes, however, constituted only 10% of all outcome domains reported and were reported infrequently. Psychological problems, including depression, were reported in <10% of trials. School performance, fatigue, physical function, and QOL were reported in just 1% of trials. No trials reported on social participation. The omission of outcomes important to children with CKD can hamper efforts to implement interventions and strategies to optimize outcomes that are meaningful to patients themselves. Further work is needed to identify dimensions of QOL that are important to patients and subsequently develop feasible and validated measures to use in trials.
There also was a paucity of outcomes identified as important to parents, who have a central role in monitoring and managing the health and treatment of their child. Physical, cognitive, and social-emotional development have been identified as a major parental concern. 56, 61 Linear growth (height and pubertal development and weight/BMI/body composition) were both reported in >25% of trials; however, no trials reported on neurocognitive development. Furthermore, parents share their children's concerns regarding school performance, social participation, and mortality, all of which were underreported. 56, 61 We acknowledge that mortality rates are low in the pediatric population. The omission of outcomes that are of explicit importance to children and parents, however, can diminish the relevance of trials.
In the 55 dialysis-specific trials, 4 of the 5 most commonly reported outcomes were surrogate markers: phosphate (21 [ We also have demonstrated substantial multiplicity and inconsistency in outcome domains and measures across trials in children with CKD, with 6158 outcome measures and time points reported across the 100 outcome domains. Blood pressure (the most frequently reported outcome) was measured in 37% of trials; however, it had 56 different outcome measures. Without consistency in the way outcomes are measured and reported, it is difficult to assess the relative effect of interventions across studies. 63 Furthermore, the majority of trials had a duration <24 months (63.4%) and a small sample size of 1-50 patients (62%), leading to considerable imprecision regarding treatment effects and uncertainty on the longterm impact of any treatment decisions.
A number of other studies have evaluated systematically the reporting of outcome domains in trials of pediatric conditions such as asthma, 56 autism, 64 appendicitis, 65 acute diarrheal illness, 26 neurodisability, 66 cerebral palsy, 67 and otitis media. 68 These reviews have identified similar problems in outcome reporting. There is a dominance of clinical and physiological markers of short-term disease activity and in contrast limited focus of QOL, functional status, and long-term outcomes. Previous studies also have demonstrated a marked inconsistency across trials in the way that outcomes are measured and reported, nonuniformity in the definitions of clinical events used as endpoints, a lack of clarity in reporting methods, and problems with reporting bias. [24] [25] [26] 56, 64, 65 This work provides a comprehensive and detailed analysis of the range and consistency of outcome domains and measures reported in trials in children across all stages of CKD; however, this review has some limitations. We used Cochrane reviews as a sampling frame because it was not feasible to include all trials; however, the reviews cover the topics of importance in the field. We did not appraise the risk of bias in the included trials given our focus on the reporting of outcomesnot the results. Non-English trials were excluded, and most studies were conducted in high-income countries.
Our findings emphasize the importance of developing a minimum set of core outcomes to be measured and reported in randomized controlled trials. Core outcome sets increase the likelihood that important outcomes will be measured, improve evidence synthesis by reducing heterogeneity between studies, and reduce outcome reporting bias. 56 Core outcome sets have been developed for other medical conditions, and the Core Outcome Measures in Effectiveness Trials database 69 contains >120 studies on the development of core outcome sets. Studies in the pediatric setting, however, are scarce, although work has been done in the areas of otitis media, 61, 68 asthma, 56 neurodisability, 66 autism, 64 and cerebral palsy. 67 No core outcome set exists in pediatric CKD.
The Standardized Outcomes in Nephrology Initiative, which commenced in 2014, aims to established a core outcome set across the spectrum of CKD that is based on the shared priorities of all stakeholders. 70 Standardized Outcomes in Nephrology-Kids is now underway, engaging children, parents, and health professionals in a process to develop a core outcome set for trials in children and adolescents across all stages of CKD. 71 There is a clear dominance of surrogate outcomes reported in trials in children with CKD, whereas outcomes that have direct relevance for children, their parents, and clinicians are relatively rare. Furthermore, the heterogeneity and inconsistency in the way outcomes are defined, assessed, and measured also limits ability to synthesize results across studies, including those assessing similar interventions. This reiterates an urgent need to improve the relevance and reliability of trials in decision making through the development of a core outcomes set to be reported as a minimum in trials in children with CKD. A core outcome set can be expected to improve outcome reporting in trials and subsequently lead to enhanced QOL, treatment satisfaction, and health outcomes of children and adolescents with CKD. ■ Submitted for publication Dec 16, 2016 
